David Zaccardelli, Verona Pharma CEO

Verona’s COPD drug shines in PhI­II study, po­ten­tial­ly clear­ing path to FDA — shares jump

UK-based Verona Phar­ma’s COPD drug, en­sifen­trine, has suc­ceed­ed in its Phase III tri­al, paving the way for a pos­si­ble FDA ap­proval.

In Verona’s Phase III …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.